{"transactions":[{"id":730650,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-22T20:15:05.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":51000,"derivative":{"exercise_price":3.62,"expiration_date":"2036-06-17","underlying":"Class A Ordinary Shares","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0001752139-26-000002","document":"form4-06222026_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000175213926000002/form4-06222026_040601.xml","form_type":"4"}},{"id":1130670,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-05-30T01:39:50.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in twelve substantially equal monthly installments over a one-year period measured from May 21, 2025; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":51000,"derivative":{"exercise_price":1.02,"expiration_date":"2035-05-29","underlying":"Class A Ordinary Shares","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0001415889-25-014939","document":"form4-05302025_010547.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000141588925014939/form4-05302025_010547.xml","form_type":"4"}},{"id":1134733,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T20:05:14.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":92158,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":0,"derivative":{"exercise_price":4.46,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":92158},"source":{"system":"sec-edgar","filing":"0001962918-25-000052","document":"wk-form4_1748030700.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1752139/000196291825000052/wk-form4_1748030700.xml","form_type":"4"}},{"id":1134732,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T20:05:14.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23243,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001962918-25-000052","document":"wk-form4_1748030700.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1752139/000196291825000052/wk-form4_1748030700.xml","form_type":"4"}},{"id":1134731,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T20:05:14.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the \"Merger Agreement\") with Alumis, Inc., a Delaware corporation (\"Parent\"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the \"Exchange Ratio\") shares of voting common stock of Parent, par value $0.0001 per share (\"Parent Common Stock\"), and cash in lieu of any fractional shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001962918-25-000052","document":"wk-form4_1748030700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1752139/000196291825000052/wk-form4_1748030700.xml","form_type":"4"}},{"id":1451032,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-19T22:18:44.000Z","date":"2024-07-17","kind":"sale","planned":false,"acquired":false,"shares":1,"price":6.86,"value":6.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Dr. Becker sold 1 share to AI Acel LLC (\"AI\"), an affiliate of his employer Access Industries, Inc., in an off-market transaction in connection with AI's July 2023 filing for clearance under the Hart-Scott-Rodino Act (\"HSR\"), which requires AI to purchase additional shares of the Company in advance of the second filing threshold. The share was sold for $6.86, which was the market closing price for the Company's shares on July 17, 2024."}],"balance_after":2999,"source":{"system":"sec-edgar","filing":"0001962918-24-000099","document":"wk-form4_1721427517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1752139/000196291824000099/wk-form4_1721427517.xml","form_type":"4"}},{"id":1482872,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-06-11T23:14:03.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":92158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":92158,"derivative":{"exercise_price":4.46,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":92158},"source":{"system":"sec-edgar","filing":"0001962918-24-000093","document":"wk-form4_1718147636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1752139/000196291824000093/wk-form4_1718147636.xml","form_type":"4"}},{"id":1843992,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to buy Common Stock)","published_at":"2023-06-26T23:15:02.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 22, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":37500,"derivative":{"exercise_price":12.69,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-23-039802","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1752139/000120919123039802/doc4.xml","form_type":"4"}},{"id":1896301,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:02:33.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":23243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":23243,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001209191-23-028874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1752139/000120919123028874/doc4.xml","form_type":"4"}},{"id":1896300,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:02:33.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":23243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Class A Common Stock","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001209191-23-028874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1752139/000120919123028874/doc4.xml","form_type":"4"}},{"id":1896299,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-12T01:02:33.000Z","date":"2023-05-09","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":18,"value":54000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the \"IPO\")."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-23-028874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1752139/000120919123028874/doc4.xml","form_type":"4"}},{"id":1903997,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-05T00:11:49.000Z","date":"2023-05-04","kind":"grant","planned":false,"acquired":true,"shares":23243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."}],"balance_after":23243,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Class A Common","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001209191-23-027524","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1752139/000120919123027524/doc4.xml","form_type":"4"}},{"id":2222688,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to buy Common Stock)","published_at":"2022-06-23T22:08:36.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":28700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12th of the total shares on each monthly anniversary, beginning on July 21, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":28700,"derivative":{"exercise_price":16.29,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":28700},"source":{"system":"sec-edgar","filing":"0001209191-22-039047","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1752139/000120919122039047/doc4.xml","form_type":"4"}},{"id":2688424,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2021-06-02T01:50:31.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on June 26, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The Reporting Person is reporting the acquisition of these securities pursuant to Rule 16a-2(a) of the Exchange Act."}],"balance_after":63000,"derivative":{"exercise_price":16,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0001209191-21-037023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1752139/000120919121037023/doc4.xml","form_type":"4"}},{"id":2688423,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T01:50:31.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":5000,"price":16,"value":80000.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-21-037023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1752139/000120919121037023/doc4.xml","form_type":"4"}},{"id":2764516,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-04-01T19:49:34.000Z","date":"2021-04-01","kind":"disposition_to_issuer","acquired":false,"shares":13997,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All options were vested and exercisable as of immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":13997},"source":{"system":"sec-edgar","filing":"0000899243-21-014451","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924321014451/doc4.xml","form_type":"4"}},{"id":2764515,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T19:49:34.000Z","date":"2021-04-01","kind":"other","acquired":false,"shares":2827883,"price":60,"value":169672980.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the \"Company\"), Merck Sharp & Dohme Corp. (\"Merck\") and Panama Merger Sub, Inc. (\"Merger Sub\"), Merger Sub commenced a tender offer (the \"Offer\") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the \"Offer Price\"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the \"Merger\") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were cancelled and converted automatically into the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported are held directly by AI Pan LLC (\"AI Pan\"). Each of Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik may be deemed to beneficially own the Company's shares beneficially owned by AI Pan, a subsidiary in a multi-tier corporate structure of which Access Industries Holdings LLC is the parent holding company and is ultimately managed by Access Industries Management, LLC and controlled by Mr. Blavatnik. Mr. Becker is a biotechnology principal of Access Industries, Inc., an affiliate of Access Industries Management LLC, and does not have voting or dispositive power over the shares held by AI Pan. Mr. Becker disclaims beneficial ownership of the shares held by AI Pan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924321014451/doc4.xml","form_type":"4"}},{"id":2764514,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T19:49:34.000Z","date":"2021-04-01","kind":"other","acquired":false,"shares":1000,"price":60,"value":60000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the \"Company\"), Merck Sharp & Dohme Corp. (\"Merck\") and Panama Merger Sub, Inc. (\"Merger Sub\"), Merger Sub commenced a tender offer (the \"Offer\") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the \"Offer Price\"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the \"Merger\") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were cancelled and converted automatically into the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924321014451/doc4.xml","form_type":"4"}},{"id":2970044,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-23T17:30:08.000Z","date":"2020-11-19","kind":"purchase","acquired":true,"shares":197716,"price":15.12,"value":2989465.92,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.94 per share to $15.39 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported are held directly by AI Pan LLC (\"AI Pan\"). Each of Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik may be deemed to beneficially own the Issuer's shares beneficially owned by AI Pan, a subsidiary in a multi-tier corporate structure of which Access Industries Holdings LLC is the parent holding company and is ultimately managed by Access Industries Management, LLC and controlled by Mr. Blavatnik. Mr. Becker is a biotechnology principal of Access Industries, Inc., an affiliate of Access Industries Management LLC, and does not have voting or dispositive power over the shares held by AI Pan. Mr. Becker disclaims beneficial ownership of the shares held by AI Pan."}],"balance_after":2827883,"source":{"system":"sec-edgar","filing":"0000899243-20-031941","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320031941/doc4.xml","form_type":"4"}},{"id":2973409,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T20:15:04.000Z","date":"2020-11-18","kind":"purchase","acquired":true,"shares":14197,"price":15.26,"value":216646.22,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.10 per share to $15.50 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported are held directly by AI Pan LLC (\"AI Pan\"). Each of Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik may be deemed to beneficially own the Issuer's shares beneficially owned by AI Pan, a subsidiary in a multi-tier corporate structure of which Access Industries Holdings LLC is the parent holding company and is ultimately managed by Access Industries Management, LLC and controlled by Mr. Blavatnik. Mr. Becker is a biotechnology principal of Access Industries, Inc., an affiliate of Access Industries Management LLC, and does not have voting or dispositive power over the shares held by AI Pan. Mr. Becker disclaims beneficial ownership of the shares held by AI Pan."}],"balance_after":2630167,"source":{"system":"sec-edgar","filing":"0000899243-20-031744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320031744/doc4.xml","form_type":"4"}},{"id":2973408,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T20:15:04.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":13027,"price":15.43,"value":201006.61,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.20 per share to $15.50 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported are held directly by AI Pan LLC (\"AI Pan\"). Each of Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik may be deemed to beneficially own the Issuer's shares beneficially owned by AI Pan, a subsidiary in a multi-tier corporate structure of which Access Industries Holdings LLC is the parent holding company and is ultimately managed by Access Industries Management, LLC and controlled by Mr. Blavatnik. Mr. Becker is a biotechnology principal of Access Industries, Inc., an affiliate of Access Industries Management LLC, and does not have voting or dispositive power over the shares held by AI Pan. Mr. Becker disclaims beneficial ownership of the shares held by AI Pan."}],"balance_after":2615970,"source":{"system":"sec-edgar","filing":"0000899243-20-031744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320031744/doc4.xml","form_type":"4"}},{"id":2973407,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T20:15:04.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":2170,"price":14.63,"value":31747.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.20 per share to $15.00 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported are held directly by AI Pan LLC (\"AI Pan\"). Each of Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik may be deemed to beneficially own the Issuer's shares beneficially owned by AI Pan, a subsidiary in a multi-tier corporate structure of which Access Industries Holdings LLC is the parent holding company and is ultimately managed by Access Industries Management, LLC and controlled by Mr. Blavatnik. Mr. Becker is a biotechnology principal of Access Industries, Inc., an affiliate of Access Industries Management LLC, and does not have voting or dispositive power over the shares held by AI Pan. Mr. Becker disclaims beneficial ownership of the shares held by AI Pan."}],"balance_after":2602943,"source":{"system":"sec-edgar","filing":"0000899243-20-031744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320031744/doc4.xml","form_type":"4"}},{"id":3021552,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-09-28T17:24:20.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":10240,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":62.66,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-20-052229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120052229/doc4.xml","form_type":"4"}},{"id":3021551,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-09-28T17:24:20.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":10240,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":31.77,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-20-052229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120052229/doc4.xml","form_type":"4"}},{"id":3021550,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-09-28T17:24:20.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":20475,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2028-09-12","underlying":"Common Stock","underlying_shares":20475},"source":{"system":"sec-edgar","filing":"0001209191-20-052229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120052229/doc4.xml","form_type":"4"}},{"id":3021549,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-28T17:24:20.000Z","date":"2020-09-28","kind":"other","acquired":false,"shares":667600,"price":100,"value":66760000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-052229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120052229/doc4.xml","form_type":"4"}},{"id":3078844,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-07-21T19:39:16.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":9579462,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by AI Pan LLC. Access Industries Management, LLC (\"Access LLC\") is AI Pan LLC's manager. Len Blavatnik is the manager of Access LLC, and may be deemed to have sole voting and dispositive power over the shares held by AI Pan LLC. Mr. Becker is a biotechnology principal of Access Industries, Inc., an affiliate of Access LLC, and does not have voting or dispositive power over the shares held by AI Pan LLC. Mr. Becker disclaims beneficial ownership of the shares held by AI Pan LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1878551},"source":{"system":"sec-edgar","filing":"0000899243-20-019874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320019874/doc4.xml","form_type":"4"}},{"id":3078843,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-21T19:39:16.000Z","date":"2020-07-17","kind":"grant","acquired":true,"shares":13997,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option award was granted on July 17, 2020. The shares underlying the award vest in equal monthly installments following July 17, 2020 through July 17, 2023, subject to the reporting person's continued service on each applicable vesting date."}],"balance_after":13997,"derivative":{"exercise_price":18,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":13997},"source":{"system":"sec-edgar","filing":"0000899243-20-019874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320019874/doc4.xml","form_type":"4"}},{"id":3078842,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-21T19:39:16.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":1000,"price":18,"value":18000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0000899243-20-019874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320019874/doc4.xml","form_type":"4"}},{"id":3078841,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-21T19:39:16.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":722222,"price":18,"value":12999996.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by AI Pan LLC. Access Industries Management, LLC (\"Access LLC\") is AI Pan LLC's manager. Len Blavatnik is the manager of Access LLC, and may be deemed to have sole voting and dispositive power over the shares held by AI Pan LLC. Mr. Becker is a biotechnology principal of Access Industries, Inc., an affiliate of Access LLC, and does not have voting or dispositive power over the shares held by AI Pan LLC. Mr. Becker disclaims beneficial ownership of the shares held by AI Pan LLC."}],"balance_after":2600773,"source":{"system":"sec-edgar","filing":"0000899243-20-019874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320019874/doc4.xml","form_type":"4"}},{"id":3078840,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-21T19:39:16.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":1878551,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by AI Pan LLC. Access Industries Management, LLC (\"Access LLC\") is AI Pan LLC's manager. Len Blavatnik is the manager of Access LLC, and may be deemed to have sole voting and dispositive power over the shares held by AI Pan LLC. Mr. Becker is a biotechnology principal of Access Industries, Inc., an affiliate of Access LLC, and does not have voting or dispositive power over the shares held by AI Pan LLC. Mr. Becker disclaims beneficial ownership of the shares held by AI Pan LLC."}],"balance_after":1878551,"source":{"system":"sec-edgar","filing":"0000899243-20-019874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320019874/doc4.xml","form_type":"4"}},{"id":3118178,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-06-08T20:03:55.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":10240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":10240,"derivative":{"exercise_price":62.66,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-20-035140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120035140/doc4.xml","form_type":"4"}},{"id":3360838,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-22T20:07:02.000Z","date":"2019-11-20","kind":"purchase","acquired":true,"shares":55000,"price":29.94,"value":1646700.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price represents the weighted average price of the shares purchased. The purchase price ranged from $29.575 to $30.145 per share.  Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":667600,"source":{"system":"sec-edgar","filing":"0001209191-19-057879","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919119057879/doc4.xml","form_type":"4"}},{"id":3385252,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-30T16:16:51.000Z","date":"2019-10-29","kind":"purchase","acquired":true,"shares":9196,"price":33.9797,"value":312477.3212,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Price represents the weighted average price of the shares purchased.  The purchase price ranged from $33.50 to $34.00 per share.  Upon request by the Commission staff, the Issuer or the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":612600,"source":{"system":"sec-edgar","filing":"0001209191-19-054503","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919119054503/doc4.xml","form_type":"4"}},{"id":3385251,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-30T16:16:51.000Z","date":"2019-10-28","kind":"purchase","acquired":true,"shares":68404,"price":33.4125,"value":2285548.65,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price represents the weighted average price of the shares purchased.  The purchase price ranged from $32.66 to $33.65 per share.  Upon request by the Commission staff, the Issuer or the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":603404,"source":{"system":"sec-edgar","filing":"0001209191-19-054503","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919119054503/doc4.xml","form_type":"4"}},{"id":3389661,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-22T16:06:58.000Z","date":"2019-10-18","kind":"purchase","acquired":true,"shares":535000,"price":28,"value":14980000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of Common Stock of Principia Biopharma Inc. (the \"Issuer\") that were purchased in connection with the Issuer's public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units.  The units owned by the Reporting Person do  not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":535000,"source":{"system":"sec-edgar","filing":"0001209191-19-053770","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919119053770/doc4.xml","form_type":"4"}},{"id":3493799,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-06-11T18:51:49.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":10240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":10240,"derivative":{"exercise_price":31.77,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-19-036235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919119036235/doc4.xml","form_type":"4"}},{"id":3697971,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-01-10T21:43:48.000Z","date":"2018-09-13","kind":"grant","acquired":true,"shares":20475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over a three year period, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":20475,"derivative":{"exercise_price":17,"expiration_date":"2028-09-12","underlying":"Common Stock","underlying_shares":20475},"source":{"system":"sec-edgar","filing":"0001209191-19-003363","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919119003363/doc4.xml","form_type":"4"}},{"id":3810464,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2018-09-20T18:58:17.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":167537,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. (\"BPO-II\"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Each of Ronald M. Hunt, Vijay K. Lathi, Liam T. Ratcliffe and Isaac J. Manke, the managers of BPO\nManagement-II (each, a \"BPO-II Manager\" and collectively, the \"BPO-II Managers\"), and Becker may each, by virtue of their respective affiliations with and/or interests in New Leaf Ventures, be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of the BPO-II Managers and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":167537},"source":{"system":"sec-edgar","filing":"0001209191-18-051835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919118051835/doc4.xml","form_type":"4"}},{"id":3810463,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-3 Convertible Preferred Stock","published_at":"2018-09-20T18:58:17.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":544047,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures II, L.P. (\"NLV-II\"). The general partner of NLV-II is New Leaf Venture Associates II, L.P. (\"NLVA-II\"). The general partner of NLVA-II is New Leaf Venture Management II, L.L.C. (\"Management-II\"). Each of NLVA-II and Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-II or Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-II (each, a \"NLV-II Manager\" and collectively, the \"NLV-II Managers\"), and Daniel J. Becker (\"Becker\"), a member of the Issuer's board of directors and principal of New Leaf Venture Partners, L.L.C. (together with its affiliates, \"New Leaf Ventures\"), may each, by virtue of their respective affiliations with and/or interests in New Leaf Ventures, be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the NLV-II Managers and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":544047},"source":{"system":"sec-edgar","filing":"0001209191-18-051835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919118051835/doc4.xml","form_type":"4"}},{"id":3810462,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Convertible Preferred Stock","published_at":"2018-09-20T18:58:17.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":260617,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures II, L.P. (\"NLV-II\"). The general partner of NLV-II is New Leaf Venture Associates II, L.P. (\"NLVA-II\"). The general partner of NLVA-II is New Leaf Venture Management II, L.L.C. (\"Management-II\"). Each of NLVA-II and Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-II or Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-II (each, a \"NLV-II Manager\" and collectively, the \"NLV-II Managers\"), and Daniel J. Becker (\"Becker\"), a member of the Issuer's board of directors and principal of New Leaf Venture Partners, L.L.C. (together with its affiliates, \"New Leaf Ventures\"), may each, by virtue of their respective affiliations with and/or interests in New Leaf Ventures, be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the NLV-II Managers and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":260617},"source":{"system":"sec-edgar","filing":"0001209191-18-051835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919118051835/doc4.xml","form_type":"4"}},{"id":3810461,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2018-09-20T18:58:17.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":312741,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures II, L.P. (\"NLV-II\"). The general partner of NLV-II is New Leaf Venture Associates II, L.P. (\"NLVA-II\"). The general partner of NLVA-II is New Leaf Venture Management II, L.L.C. (\"Management-II\"). Each of NLVA-II and Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-II or Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-II (each, a \"NLV-II Manager\" and collectively, the \"NLV-II Managers\"), and Daniel J. Becker (\"Becker\"), a member of the Issuer's board of directors and principal of New Leaf Venture Partners, L.L.C. (together with its affiliates, \"New Leaf Ventures\"), may each, by virtue of their respective affiliations with and/or interests in New Leaf Ventures, be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the NLV-II Managers and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":312741},"source":{"system":"sec-edgar","filing":"0001209191-18-051835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919118051835/doc4.xml","form_type":"4"}},{"id":3810460,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2018-09-20T18:58:17.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":1070771,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures II, L.P. (\"NLV-II\"). The general partner of NLV-II is New Leaf Venture Associates II, L.P. (\"NLVA-II\"). The general partner of NLVA-II is New Leaf Venture Management II, L.L.C. (\"Management-II\"). Each of NLVA-II and Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-II or Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-II (each, a \"NLV-II Manager\" and collectively, the \"NLV-II Managers\"), and Daniel J. Becker (\"Becker\"), a member of the Issuer's board of directors and principal of New Leaf Venture Partners, L.L.C. (together with its affiliates, \"New Leaf Ventures\"), may each, by virtue of their respective affiliations with and/or interests in New Leaf Ventures, be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the NLV-II Managers and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1070771},"source":{"system":"sec-edgar","filing":"0001209191-18-051835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919118051835/doc4.xml","form_type":"4"}},{"id":3810459,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T18:58:17.000Z","date":"2018-09-18","kind":"purchase","acquired":true,"shares":270000,"price":17,"value":4590000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. (\"BPO-II\"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Each of Ronald M. Hunt, Vijay K. Lathi, Liam T. Ratcliffe and Isaac J. Manke, the managers of BPO\nManagement-II (each, a \"BPO-II Manager\" and collectively, the \"BPO-II Managers\"), and Becker may each, by virtue of their respective affiliations with and/or interests in New Leaf Ventures, be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of the BPO-II Managers and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":437537,"source":{"system":"sec-edgar","filing":"0001209191-18-051835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919118051835/doc4.xml","form_type":"4"}},{"id":3810458,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T18:58:17.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":167537,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. (\"BPO-II\"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Each of Ronald M. Hunt, Vijay K. Lathi, Liam T. Ratcliffe and Isaac J. Manke, the managers of BPO\nManagement-II (each, a \"BPO-II Manager\" and collectively, the \"BPO-II Managers\"), and Becker may each, by virtue of their respective affiliations with and/or interests in New Leaf Ventures, be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of the BPO-II Managers and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":167537,"source":{"system":"sec-edgar","filing":"0001209191-18-051835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919118051835/doc4.xml","form_type":"4"}},{"id":3810457,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T18:58:17.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":544047,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures II, L.P. (\"NLV-II\"). The general partner of NLV-II is New Leaf Venture Associates II, L.P. (\"NLVA-II\"). The general partner of NLVA-II is New Leaf Venture Management II, L.L.C. (\"Management-II\"). Each of NLVA-II and Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-II or Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-II (each, a \"NLV-II Manager\" and collectively, the \"NLV-II Managers\"), and Daniel J. Becker (\"Becker\"), a member of the Issuer's board of directors and principal of New Leaf Venture Partners, L.L.C. (together with its affiliates, \"New Leaf Ventures\"), may each, by virtue of their respective affiliations with and/or interests in New Leaf Ventures, be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the NLV-II Managers and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2188176,"source":{"system":"sec-edgar","filing":"0001209191-18-051835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919118051835/doc4.xml","form_type":"4"}},{"id":3810456,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T18:58:17.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":260617,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures II, L.P. (\"NLV-II\"). The general partner of NLV-II is New Leaf Venture Associates II, L.P. (\"NLVA-II\"). The general partner of NLVA-II is New Leaf Venture Management II, L.L.C. (\"Management-II\"). Each of NLVA-II and Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-II or Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-II (each, a \"NLV-II Manager\" and collectively, the \"NLV-II Managers\"), and Daniel J. Becker (\"Becker\"), a member of the Issuer's board of directors and principal of New Leaf Venture Partners, L.L.C. (together with its affiliates, \"New Leaf Ventures\"), may each, by virtue of their respective affiliations with and/or interests in New Leaf Ventures, be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the NLV-II Managers and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1644129,"source":{"system":"sec-edgar","filing":"0001209191-18-051835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919118051835/doc4.xml","form_type":"4"}},{"id":3810455,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T18:58:17.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":312741,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures II, L.P. (\"NLV-II\"). The general partner of NLV-II is New Leaf Venture Associates II, L.P. (\"NLVA-II\"). The general partner of NLVA-II is New Leaf Venture Management II, L.L.C. (\"Management-II\"). Each of NLVA-II and Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-II or Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-II (each, a \"NLV-II Manager\" and collectively, the \"NLV-II Managers\"), and Daniel J. Becker (\"Becker\"), a member of the Issuer's board of directors and principal of New Leaf Venture Partners, L.L.C. (together with its affiliates, \"New Leaf Ventures\"), may each, by virtue of their respective affiliations with and/or interests in New Leaf Ventures, be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the NLV-II Managers and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1383512,"source":{"system":"sec-edgar","filing":"0001209191-18-051835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919118051835/doc4.xml","form_type":"4"}},{"id":3810454,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36378,"kind":"person","name":"Becker Daniel J.","position":1,"cik":"0001752139","reported_name":"Becker Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T18:58:17.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":1070771,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional\nconsideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures II, L.P. (\"NLV-II\"). The general partner of NLV-II is New Leaf Venture Associates II, L.P. (\"NLVA-II\"). The general partner of NLVA-II is New Leaf Venture Management II, L.L.C. (\"Management-II\"). Each of NLVA-II and Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-II or Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-II (each, a \"NLV-II Manager\" and collectively, the \"NLV-II Managers\"), and Daniel J. Becker (\"Becker\"), a member of the Issuer's board of directors and principal of New Leaf Venture Partners, L.L.C. (together with its affiliates, \"New Leaf Ventures\"), may each, by virtue of their respective affiliations with and/or interests in New Leaf Ventures, be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the NLV-II Managers and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1070771,"source":{"system":"sec-edgar","filing":"0001209191-18-051835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919118051835/doc4.xml","form_type":"4"}}]}